SAB Biotherapeutics to Showcase SAB-142 Data at Key Diabetes and Immunology Conferences

Event summary

  • SAB Biotherapeutics will present data on SAB-142 at ADA’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting in June.
  • Oral presentation at ADA on June 5, 2026, focusing on safety, pharmacokinetics, and immunogenicity of SAB-142.
  • Poster presentation at FOCIS on June 10, 2026, highlighting clinical translation of SAB-142 from juvenile NHP studies to humans.
  • SAB-142 is a disease-modifying, redosable immunotherapy for newly diagnosed Stage 3 type 1 diabetes (T1D).
  • Topline data readout for the Phase 2b SAFEGUARD study expected in the second half of 2027.

The big picture

SAB Biotherapeutics’ presentations at ADA and FOCIS underscore the growing interest in disease-modifying immunotherapies for type 1 diabetes. The focus on SAB-142’s clinical and mechanistic profile highlights the company’s strategic push to establish its lead candidate as a potential best-in-class treatment. The upcoming topline data readout from the Phase 2b SAFEGUARD study will be critical in determining the therapeutic and commercial viability of SAB-142 in the competitive autoimmune disease market.

What we're watching

Clinical Efficacy
How the data from SAB-142’s Phase 2b SAFEGUARD study will impact its potential as a best-in-class therapy for T1D.
Regulatory Pathway
Whether the positive clinical translation data will accelerate regulatory approval timelines.
Market Positioning
The pace at which SAB Biotherapeutics can differentiate SAB-142 from existing treatments like rabbit ATG.